August 2025
1. WANG Y, Xu Z, He C, Qu H, et al
   E26 transformation-specific transcription factor 3 tips the balance: repressing tropomyosin 2 to fuel Yes-associated protein 1-driven cisplatin resistance in ovarian cancer.
   Anticancer Drugs. 2025 Aug 1. doi: 10.1097/CAD.0000000000001761.
   

   >> Share

   
   February 2025
2. XING H, Bi HN, Yin Q, Zhang J, et al
   FSP1 expression as a predictor of platinum resistance and recurrence in epithelial ovarian cancer.
   Anticancer Drugs. 2025 Feb 11. doi: 10.1097/CAD.0000000000001676.
   

   >> Share

   
   January 2025
3. LI S, Zhang Y, Yang R, Yang Q, et al
   A phase II study of anlotinib as first-line maintenance therapy for advanced ovarian cancer.
   Anticancer Drugs. 2025 Jan 29. doi: 10.1097/CAD.0000000000001698.
   

   >> Share

   
   
4. MACCHIA G, Pezzulla D, Russo D, Campitelli M, et al
   Stereotactic body radiotherapy and poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a knowledge and attitudes survey in collaboration with the Italian Association of Radiation Oncology (AIRO) and Multicenter Italian Trials in Ovarian Cancer
   Anticancer Drugs. 2025 Jan 8. doi: 10.1097/CAD.0000000000001684.
   

   >> Share

   
   
5. WANG L, Ma S, Su H, Nie D, et al
   The impact of bevacizumab intraperitoneal perfusion combined with paclitaxel and platinum-based chemotherapy on serum stromal-derived factor-1alpha (SDF-1alpha) and chemokine ligand 5 (CXCL-5) levels in patients with ovarian cancer after tumor cell de
   Anticancer Drugs. 2025 Jan 6. doi: 10.1097/CAD.0000000000001663.
   

   >> Share

   
   October 2024
6. CHEN Q, Zhang H
   SMAC mimetic BV6 acts in synergy with mTOR inhibitor to increase cisplatin sensitivity in ovarian cancer.
   Anticancer Drugs. 2024 Oct 16. doi: 10.1097/CAD.0000000000001664.
   

   >> Share

   
   September 2024
7. MA L, Zhao X, Lu X, Shen J, et al
   KLF4 activates LATS2 to promote cisplatin sensitivity in ovarian cancer through DNA damage.
   Anticancer Drugs. 2024 Sep 27. doi: 10.1097/CAD.0000000000001662.
   

   >> Share

   
   August 2023
8. ITO K, Nakagawa M, Shimokawa M, Hori K, et al
   Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601.
   Anticancer Drugs. 2023;34:857-865.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share